Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 172-181

  Schmeink, C E ^a   Massuger, L F A G ^a   Lenselink, C H ^a   Quint, W G V ^b   Witte, B I ^c   Berkhof, J ^c   Melchers, W J G ^a   Bekkers, R L M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DDL Diagnostic Laboratory   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

clearance; HPV; human papillomavirus; incidence; women

Indexed keywords

VIRUS DNA;

ADULT; AGE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; COHORT ANALYSIS; DNA DETERMINATION; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENOTYPING TECHNIQUE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN TISSUE; INCIDENCE; LINE PROBE ASSAY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; REINFECTION; SEXUAL BEHAVIOR; UTERINE CERVIX CYTOLOGY; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS REACTIVATION; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MARITAL STATUS; NETHERLANDS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS;

EID: 84876674340     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27986     Document Type: Article

References (48)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
2. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 958-64.
3. Schiffman MH, Castle P,. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 2003; 95: E2.
4. Bekkers RL, Massuger LF, Bulten J, et al. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol 2004; 14: 95-105.
5. Rodriguez AC, Burk R, Herrero R, et al. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007; 34: 494-502.
6. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-9.
7. Oh JK, Ju YH, Franceschi S, et al. Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis 2008; 8: 13.
8. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008; 68: 8813-24.
9. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12: 485-90.
10. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106: 396-403.
11. Molano M, van den BA, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486-94.
12. Castle PE, Rodriguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009; 339: b2569.
13. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415-23.
14. Baseman JG, Koutsky LA,. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 (Suppl 1): S16-24.
15. Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 (Suppl 3): S52-S61.
16. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-26.
17. Velicer C, Zhu X, Vuocolo S, et al. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 2009; 36: 696-703.
18. Castellsague X,. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008; 110 (3 Suppl 2): S4-7.
19. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-8.
20. de SS, Quint WG, Alemany L, Geraets DT, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
21. Ting J, Kruzikas DT, Smith JS,. A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer 2010; 20: 1244-9.
22. Fukuchi E, Sawaya GF, Chirenje M, et al. Cervical Human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe. Sex Transm Dis 2009; 36: 305-11.
23. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87.
24. Bae J, Seo SS, Park YS, et al. Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol 2009; 115: 75-80.
25. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358: 1782-3.
26. Lai CH, Chao A, Chang CJ, et al. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008; 123: 1685-92.
27. Kulmala SM, Shabalova IP, Petrovitchev N, et al. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 2007; 16: 17-22.
28. Lenselink CH, Melchers WJ, Quint WG, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS ONE 2008; 3: e3743.
29. Schmeink CE, Massuger LF, Lenselink CH, et al. Effect of the menstrual cycle and hormonal contraceptives on human papillomavirus detection in young, unscreened women. Obstet Gynecol 2010; 116: 67-75.
30. Petignat P, Faltin DL, Bruchim I, et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007; 105: 530-5.
31. Ogilvie GS, Patrick DM, Schulzer M, et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005; 81: 207-12.
32. Schmeink CE, Bekkers RL, Massuger LF, et al. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011; 21: 139-53.
33. Melchers WJ, Bakkers JM, Wang J, et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol 1999; 155: 1473-8.
34. van Hamont D, van Ham MA, Bakkers JM, et al. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol 2006; 44: 3122-9.
35. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-40.
36. Moscicki AB, Ma Y, Jonte J, et al. The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2010; 19: 2055-65.
37. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002; 186: 462-9.
38. Trottier H, Franco EL,. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 (Suppl 1): S1-15.
39. Bosch FX, de SS,. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23: 213-27.
40. Kjaer SK, van den Brule AJ, Bock JE, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997; 6: 799-805.
41. Lu B, Wu Y, Nielson CM, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 2009; 199: 362-71.
42. Gonzalez P, Hildesheim A, Rodriguez AC, et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 2010; 19: 3044-54.
43. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-24.
44. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007; 16: 709-15.
45. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831-6.
46. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70: 8569-77.
47. Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115: 1150-8.
48. Taylor S, Wang C, Wright TC, et al. Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa. BMC Med 2010; 8: 40.